Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5275939
Max Phase: Preclinical
Molecular Formula: C110H174N38O21
Molecular Weight: 2364.85
Associated Items:
ID: ALA5275939
Max Phase: Preclinical
Molecular Formula: C110H174N38O21
Molecular Weight: 2364.85
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H]1NC(=O)[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CCC/C=C/CCC[C@](C)(C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C)C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)(C)C)NC1=O
Standard InChI: InChI=1S/C110H174N38O21/c1-13-60(6)84-98(165)145-85(108(8,9)10)99(166)139-77(53-81(151)152)94(161)147-109(11,42-22-16-14-15-17-23-43-110(12,102(169)144-84)146-93(160)74(40-41-80(111)150)136-95(162)79-39-29-49-148(79)100(167)78(51-63-55-130-68-33-21-19-31-66(63)68)140-89(156)71(36-26-46-126-105(117)118)134-87(154)70(132-61(7)149)35-25-45-125-104(115)116)101(168)141-76(52-64-56-123-57-131-64)92(159)143-82(58(2)3)96(163)137-72(37-27-47-127-106(119)120)88(155)135-73(38-28-48-128-107(121)122)90(157)142-83(59(4)5)97(164)138-75(50-62-54-129-67-32-20-18-30-65(62)67)91(158)133-69(86(112)153)34-24-44-124-103(113)114/h14-15,18-21,30-33,54-60,69-79,82-85,129-130H,13,16-17,22-29,34-53H2,1-12H3,(H2,111,150)(H2,112,153)(H,123,131)(H,132,149)(H,133,158)(H,134,154)(H,135,155)(H,136,162)(H,137,163)(H,138,164)(H,139,166)(H,140,156)(H,141,168)(H,142,157)(H,143,159)(H,144,169)(H,145,165)(H,146,160)(H,147,161)(H,151,152)(H4,113,114,124)(H4,115,116,125)(H4,117,118,126)(H4,119,120,127)(H4,121,122,128)/b15-14+/t60-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,82-,83-,84+,85+,109+,110+/m0/s1
Standard InChI Key: MQZAAFQTELBCAI-GDKZHRICSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2364.85 | Molecular Weight (Monoisotopic): 2363.3716 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Liu Z, Wang P, Wold EA, Song Q, Zhao C, Wang C, Zhou J.. (2021) Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer., 64 (8.0): [PMID:33822624] [10.1021/acs.jmedchem.0c01799] |
Source(1):